<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00061958</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02534</org_study_id>
    <secondary_id>DM02-172</secondary_id>
    <secondary_id>N01CM17003</secondary_id>
    <secondary_id>CDR0000302483</secondary_id>
    <nct_id>NCT00061958</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction</brief_title>
  <official_title>A Phase II Study of Arsenic Trioxide (NSC 706363) in Patients With Advanced Adenocarcinoma of the Esophagus or Gastroesophageal Junction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well arsenic trioxide works in treating patients with&#xD;
      metastatic or unresectable cancer of the esophagus or gastroesophageal junction. Drugs used&#xD;
      in chemotherapy such as arsenic trioxide use different ways to stop tumor cells from dividing&#xD;
      so they stop growing or die&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the response rate and duration of response in patients with advanced&#xD;
      adenocarcinoma of the esophagus or gastroesophageal junction treated with arsenic trioxide.&#xD;
&#xD;
      II. Determine the toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Patients receive a loading dose of arsenic trioxide IV over 2 hours on days 1-5 on week 1.&#xD;
      Beginning on week 2, patients receive a maintenance dose of arsenic trioxide IV twice weekly&#xD;
      thereafter. Courses repeat every 4 weeks for up to 1 year in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients achieving a complete response (CR) continue to&#xD;
      receive therapy for at least 6 months beyond CR.&#xD;
&#xD;
      Patients are followed every 3 months for 6 months or until disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>June 2003</start_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response (OR) defined as a complete or partial remission, evaluated using RECIST criteria</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From the time measurement criteria are met for CR or PR until the first date that recurrent or progressive disease is objectively documented, assessed up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity graded according to the Common Toxicity Criteria version 2</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Adenocarcinoma of the Esophagus</condition>
  <condition>Stage III Esophageal Cancer</condition>
  <condition>Stage IV Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (arsenic trioxide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a loading dose of arsenic trioxide IV over 2 hours on days 1-5 on week 1. Beginning on week 2, patients receive a maintenance dose of arsenic trioxide IV twice weekly thereafter. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving a CR continue to receive therapy for at least 6 months beyond CR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (arsenic trioxide)</arm_group_label>
    <other_name>Arsenic (III) Oxide</other_name>
    <other_name>Arsenic Sesquioxide</other_name>
    <other_name>Arsenous Acid Anhydride</other_name>
    <other_name>AS2O3</other_name>
    <other_name>Trisenox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the esophagus or gastroesophageal junction&#xD;
&#xD;
               -  Metastatic or unresectable local-regional disease&#xD;
&#xD;
               -  Osseous metastasis as the only site of disease not eligible&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Mediastinal or hilar lymph nodes must be at least 2.0 cm in diameter by CT scan&#xD;
                  or MRI to be considered measurable&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Performance status - Zubrod 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8 g/dL&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  SGOT and/or SGPT no greater than 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  Calcium no greater than 12 mg/dL&#xD;
&#xD;
          -  No symptomatic hypercalcemia under treatment&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No angina within the past 6 months&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No congestive heart failure within the past 6 months&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other concurrent active malignancy except nonmelanoma skin cancer or carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
               -  Prior malignancies with no evidence of disease for at least 2 years are allowed&#xD;
&#xD;
          -  No serious concurrent infection that is uncontrolled or whose control could be&#xD;
             jeopardized by complications of study therapy&#xD;
&#xD;
          -  No concurrent nonmalignant medical illness that is uncontrolled or whose control could&#xD;
             be jeopardized by complications of study therapy&#xD;
&#xD;
          -  No psychiatric disorder or other condition that would preclude study compliance&#xD;
&#xD;
          -  No prior immunotherapy (including adjuvant or preoperative regimens)&#xD;
&#xD;
          -  No concurrent biological response modifiers&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
          -  No prior chemotherapy (including adjuvant or preoperative regimens and&#xD;
             radiosensitizers)&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to major bone marrow containing areas (e.g., pelvis or lumbar&#xD;
             spine) or area that contained the indicator lesion&#xD;
&#xD;
          -  No prior radiotherapy involving 30% or more of the bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery (4 days for minor surgery) and recovered&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent antineoplastic therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaffer Ajani</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

